Mykofenolat Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolat Accord, is an immunosuppressant presented as an oral formulation for systemic use. It is employed to prevent organ transplant rejection and to treat selected autoimmune disorders such as lupus nephritis.

GNH USA supplies Mykofenolat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global logistics for regulated medicines. Customers benefit from dedicated technical support and compliance documentation throughout the procurement process.

Mycophenolate Mofetil is used as an antimetabolite immunosuppressant to inhibit lymphocyte proliferation in specific clinical settings.

Organ transplant rejection: helps prevent rejection of transplanted organs such as kidney, liver or heart. Lupus nephritis: reduces disease activity and proteinuria in patients with systemic lupus erythematosus affecting the kidneys. Bone marrow transplantation: used as part of graft‑versus‑host disease prophylaxis to lower the incidence of GVHD.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal discomfort - Headache - Upper respiratory tract infections - Elevated liver enzymes

Serious or Rare Side Effects: - Leukopenia or neutropenia leading to increased infection risk - Severe opportunistic infections (e.g., CMV, PCP) - Malignancies such as lymphomas or skin cancers - Hepatotoxicity with jaundice or hepatitis - Teratogenic effects (Category X) causing fetal malformations

Mycophenolate Mofetil requires careful monitoring and patient counseling to minimize risks. - Blood counts: monitor complete blood count regularly to detect leukopenia. - Liver function: assess hepatic enzymes periodically for signs of toxicity. - Infection risk: avoid live vaccines and promptly treat any signs of infection. - Pregnancy: contraindicated in pregnancy; ensure effective contraception for women of childbearing potential. - Renal impairment: adjust dose or monitor drug levels in patients with reduced kidney function. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Azathioprine: additive myelosuppression may lead to severe bone‑marrow toxicity. - Cholesterol‑binding resins (e.g., cholestyramine): can reduce mycophenolate absorption. - Antacids containing aluminum or magnesium: may decrease bioavailability.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase mycophenolate plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease drug exposure, risking loss of efficacy. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Vaccines: live attenuated vaccines may cause infection; assess risk versus benefit.